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Background: Changes in serum concentrations of tumor necrosis factor-α (TNF-α) and its 
soluble receptors (sTNF-R) p55 and p75 have been shown to be associated with various 
psychiatric treatments. 
Methods: Before and after treatment, serum levels of TNF-α, sTNF-R p55 and sTNF-R p75 
were measured in 38 German soldiers who had been deployed abroad and suffered from 
combat-related post-traumatic stress disorder (PTSD). Patients were randomized either to 
inpatient psychotherapy (N=21) including eye movement desensitization and reprocessing 
(EMDR) or to outpatient clinical management (N=17). Symptoms of PTSD were measured 
using the Post-traumatic Stress Diagnostic Scale (PDS). 
Results: The PDS score significantly decreased across time in both groups. Serum 
concentrations of TNF-α increased, while sTNF-R p55 and sTNF-R p75 levels decreased 
significantly. After the treatment period, we could not detect any significant difference 
regarding TNF-α, sTNF-R p55 or sTNF-R p75 levels between the inpatient psychotherapy 
group and the outpatient clinical management control group. 
Discussion: This relatively small clinical study suggests that specific inpatient psychotherapy 
but also non-specific supportive outpatient treatment for PTSD are associated with changes in 





In recent years, cytokines, which are messenger molecules of the immune system, have 
received increasing attention in psychiatric research (Borovcanin et al. 2012, Borovcanin et al. 
2013, Maes et al. 2012, Müller et al. 2015) as they can influence various types of brain cells 
and their connectivity, the production and metabolism of neurotransmitters, and 
neuroendocrine systems (Miller et al. 2013). One cytokine that has been the subject of much 
scientific interest among researchers is tumor necrosis factor (TNF)-α (Berthold-Losleben & 
Himmerich 2008). It acts via two different receptors which can be cleaved from the surface of 
different types of cells and are measurable in the serum as soluble TNF-α receptors sTNF-R 
p55 and sTNF-R p75. 
TNF-α is a glycoprotein hormone which was isolated as a soluble factor released by host cells 
that caused necrosis of a transplanted tumor (Carswell et al. 1975). It is released by 
monocytes, macrophages and other white blood cells, the endothelium, fatty tissue and several 
other body tissues and is involved in the regulation of a wide spectrum of biological processes 
including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. 
TNF-α has been implicated in a variety of diseases, including autoimmune diseases, insulin 
resistance and cancer (Ghezzi & Cerami 2005).  
Changes in the TNF-α system have been shown to be associated with a number of psychiatric 
disorders such as schizophrenia (Pandey et al. 2015, Turhan et al. 2016) and depression 
(Himmerich et al. 2008; Schmidt et al. 2014). However, in post-traumatic stress disorder 
(PTSD), results are inconsistent; some studies report increased production of TNF-α in 
patients suffering from PTSD (Chen et al. 2014; Lindqvist et al. 2014), others do not 
(Himmerich et al. 2015, Himmerich et al. 2016, Jergović et al. 2015). 
In addition to psychiatric disorders per se, psychopharmacological treatments such as 
antidepressants (Kraus et al. 2002, Munzer et al. 2013), mood stabilizers (Himmerich et al. 
2005, Himmerich et al. 2013) and antipsychotics (Himmerich et al. 2011; Kluge et al. 2009) 
have been shown to lead to changes in the TNF-α system, most often to an increase in plasma 
levels of TNF-α and its receptors. However, an increase of TNF-α production during therapy 
is not generally conceived as a favorable effect, as TNF-α is an inflammatory marker that has 
been shown to be associated with psychiatric disorders such as schizophrenia (Pandey et al. 
2015, Turhan et al. 2016) and depression (Berthold-Losleben & Himmerich 2008; Himmerich 
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et al. 2008; Schmidt et al. 2014). Moreover, animal studies have shown that TNF-α 
production increases during stressful events such as social isolation (Krügel et al. 2014). 
The effect of psychological therapies on TNF-α levels is less clear. Studies indicate that 
dynamic psychotherapy (Del Grande da Silva et al. 2016) and cognitive behavior therapy, but 
not narrative cognitive therapy (Moreira et al. 2015), may lead to decreased TNF-α 
production in depressed patients. To our knowledge, the effect of psychotherapy for PTSD on 
serum levels of TNF-α or its receptors has never been reported. To investigate this, we 





Participants: In a cross-sectional study we examined 135 male German soldiers, 38 of whom 
had served deployments abroad and were diagnosed with combat-related PTSD according to 
ICD-10 criteria as a consequence of their deployments (Himmerich et al. 2015, Himmerich et 
al. 2016). To be included into this study, the deployment with the event leading to PTSD had 
to be no more than 24 months ago. 
For the present longitudinal investigation, the 38 patients with PTSD were randomly allocated 
to six weeks of either immediate inpatient psychotherapy (N=21) or outpatient clinical 
management control group (N=17). The latter patients were placed on a waiting list for later 
inpatient psychotherapy. 
Treatment conditions: Inpatient psychotherapy comprised of 6 weeks of treatment on a 
specialized ward within the Department of Psychiatry, Psychotherapy and 
Psychotraumatology at the Bundeswehr Hospital in Berlin, Germany. The treatment package 
included individual eye movement desensitization and reprocessing (EMDR) treatment as 
well as psychotherapeutic groups, physiotherapy, occupational and art therapy. Outpatient 
clinical management included less structured supportive psychological therapy sessions. This 
group did not receive EMDR treatment. Both patient groups were allowed 
psychopharmacological treatments as determined by the doctor and patient, without 
interference. 
Psychological measures: PSTD symptomatology was measured using the Post-traumatic 
Stress Diagnostic Scale (PDS) German version at baseline (at inpatient admission or 
allocation to clinical outpatient management) and after treatment (at discharge or after six 
weeks of outpatient treatment). The PDS was developed and validated by Foa et al. (Foa et al. 
1995) to provide a reliable self-report measure of PTSD. Its questions relate to the frequency 
of distressing and intrusive thoughts, posttraumatic avoidance and hyperarousal. The PDS has 
been shown to have high reliability and validity in measuring PTSD symptoms (McCarthy et 
al. 2008). 
Cytokine measurement: After blood drawing at baseline and after treatment, serum probes 
were immediately centrifuged at 3000 rpm for 10 min. The supernatant was aliquoted and 
stored in non-absorbing polypropylene tubes of 300 μl. Probes were shock-frozen in liquid 
nitrogen and stored in freezers at -80 ºC until further measurement. TNF-α and its soluble 
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receptors sTNF-R p55 and p75 were measured in the serum using a Bio-Plex Pro™ human 
cytokine immunoassay from Bio Rad, Germany. An implausible outlier of TNF-α > 100 
pg/ml (n=1) was excluded from the analysis. 
Statistics: Repeated measures ANOVAs (group: inpatient psychotherapy; outpatient control) 
x (time: baseline; post-treatment) were used to examine effects of treatment condition on the 
dependent measures of PDS and cytokine levels. Concurrent medication was dichotomized 
into two groups, those receiving antidepressants and those receiving  homeopathic or no 
medication, and analyzed by repeated measures ANOVAs (Medication: on antidepressants; 
not on antidepressants) x (time: baseline; post-treatment) for TNF-α and its soluble receptors. 
All statistical tests were performed using SPSS 21. As this was a pilot study, we accepted an 
uncorrected p-value of p < .05 as an indicator of statistical significance. 
Ethics: The study was approved by the local ethics committee (Ethikausschuss Charité, 




Psychosocial group characteristics: Mean age of the whole study sample (including the 
inpatient and outpatient treatment groups) was 28.5 (±5.6) years, and the average body mass 
index (BMI) was 27.3 (±3.4) kg/m2. Age, BMI and PDS score are shown separately for each 
treatment group in Table 1. At baseline, the whole sample showed a PDS score of 31.5 
(±10.5) and after treatment a score of 28.1 (±13.2), demonstrating a significant decrease over 
time [F(1, 28)=6.39, p<.05]. There was no significant main effect of group [F(1, 28)<1, n.s.] 
or group x time interaction. 
Parameters of the TNF-α system: Table 1 also shows the serum concentrations of TNF-α and 
its soluble receptors sTNF-R p55 and sTNF-R p75 separately for both treatment groups. 
Regarding the whole group, there was a significant increase over time with regard to TNF-α 
[F(1, 29)=81.03,p<.001], contrasting with a significant decrease to its receptors sTNF-R p55 
[F(1, 31)=8.94, p<.01] and sTNF-R p75 [F(1, 28)=4.82, p<.05]. No significant main effect of 
group or group x time interaction was detected for TNF-α, sTNF-R p55 and sTNF-R p75 
serum concentrations [all: F(1, 28-31)<1, n.s.].  
 
----- Insert Table 1 here. ------ 
 
Influence of antidepressant medication: We compared patients taking antidepressants (N=16) 
with those using homeopathic remedies or no psychotropic medication. No statistically 
significant differences were found for TNF-α, sTNF-R p55 and sTNF-R p75. In a consecutive 
ANCOVA controlling for medication all previously detected statistical effects remained 
significant: TNF-α [F(1, 28)=10.81, p<.01]; sTNF-R p55 [F(1, 29)=5.41, p<.05] and sTNF-R 
p75 [F(1, 26)=5.10, p<.05]. We also calculated spearman rank correlations between the 
changes in the TNF-α system and the PDS scores. No statistically significant correlations 





Both treatment groups showed a significant decrease in PTSD symptoms after treatment as 
measured by the PDS score. In addition, whereas TNF-α concentrations increased, sTNF-R 
p55 and sTNF-R p75 levels decreased significantly over time in the whole study sample. To 
our knowledge, this is the first study investigating possible changes within the TNF-α system 
during psychological treatment for PTSD. Therefore, the present investigation suggests that 
clinical improvement following PTSD treatment might influence the production or release of 
TNF-α and sTNF-Rs. 
Changes of TNF-α, sTNF-R p55 and sTNF-R p75 levels during psychological treatment could 
theoretically be due to a degree of recovery from PTSD or represent an effect or side effect of 
psychotherapy. However, our previous study did neither show any correlation between serum 
levels of TNF-α, sTNF-R p55 or sTNF-R p75 and the PDS scores in this patient sample 
(Himmerich et al. 2015) nor any statistically significant difference of TNF-α, sTNF-R p55 or 
sTNF-R p75 serum levels of soldiers with PTSD compared to those without PTSD 
(Himmerich et al. 2016). Consistent with these findings, in the present study we did not find 
any statistically significant association between the decrease in the PDS score and the changes 
in the parameters of the TNF-α system. Therefore, it seems unlikely that TNF-α, sTNF-R p55 
or sTNF-R p75 levels changed as a result of an improvement of PTSD symptoms.  
As animal studies have shown that TNF-α production increases during stressful events 
(Krügel et al. 2014), one consideration may be that EMDR therapy, which includes 
imagination of a trauma, or being allocated to outpatient clinical management, instead of a 
perceived more favorable specific psychological treatment for PTSD (e.g. inpatient 
psychotherapy), could also lead to stress. Therefore, an increase of TNF-α production or 
release could be a side effect of psychotherapy or a result of patient disappointment.  
From a psychopharmacological perspective, the increase of TNF-α production we observed is 
not surprising, since a number of effective psychopharmacological drugs, such as mirtazapine 
(Kraus et al. 2002), carbamazepine and lithium (Himmerich et al. 2005), clozapine and 
olanzapine (Kluge et al. 2009), have also been shown to lead to changes in the TNF-α system. 
TNF-α has been implicated in the development of autoimmune diseases (Ghezzi & Cerami 
2005). For example, its elevation during lithium therapy has been thought to play a role in the 
appearance or exacerbation of psoriasis or hypothyroidism, a side effect of lithium therapy 
(Petersein et al. 2015). Increased production of TNF-α during lithium therapy is seen as an 
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advantage for patients suffering from human immunodeficiency virus (HIV) infection 
(Petersein et al. 2015). However, the effects of psychotherapy on the cytokine system and 
their consequences for the course of infectious diseases and autoimmune disorders have 
scarcely been investigated. While this may be an interesting question to arise from the results 
of the present study, our data should not be used to draw far-reaching conclusions in terms of 
a direct effect of psychotherapy on the immune system. 
The changes in the TNF-α system observed could also be a consequence of psychotherapy 
leading to the intended effects of treatment, as short-term stress and activation of 
physiological parameters during psychotherapy could result in long-term improvement. This 
idea has already been considered in other areas of psychotherapy in terms of changes in 
cortisol production during stress. For example, in eating disorders, mirror confrontation leads 
to an increase in skin conductance and saliva cortisol concentration (Vocks et al. 2007). Such 
an increase in saliva cortisol has also been reported during in-vivo exposure of agoraphobic 
patients (Schumacher et al. 2014). Furthermore, basic research in humans and animals has 
shown that cortisol can enhance memory consolidation of new information, but impair 
memory retrieval of already stored information (de Quervain et al. 2009). On the basis of 
these known effects on memory processes, it has been proposed that cortisol enhances 
exposure therapy through two mechanisms: 1) cortisol-induced reduction of memory 
retrieval: an aversive cue is no longer followed by the usual, full-blown retrieval of fear 
memory and; 2) cortisol is known to enhance memory consolidation of new information and 
is assumed to enhance the storage of corrective experiences (de Quervain et al. 2011, Lass-
Hennemann & Michael 2014). Therefore, cytokine activation during psychotherapy could 
also theoretically have favorable effects which are yet to be determined. 
However, it may be that not psychotherapy itself, but rather behavioural consequences of 
psychotherapy or the behavioural changes associated with returning home after deployment 
have caused the observed alterations within the TNF-α system. Such changes could be due to 
nicotine or alcohol consumption, lifestyle, physical activity or diet. Unfortunately, we did not 
gather data on these factors longitudinally. Furthermore, the simple change of location and the 
consecutive adaptations within the immune system should also be taken into account when 
interpreting the present data. 
The TNF-α parameters did not significantly differ between the inpatient psychotherapy group 
and the outpatient clinical management group. Therefore, inpatient psychotherapy (including 
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EMDR) does not seem to exert a specific influence on TNF-α, sTNF-R p55 and sTNF-R p75 
serum concentrations. Rather, as changes were observed in both treatment groups, a non-
specific effect of psychotherapy could have contributed. This is supported by studies in 
depressed patients showing that cognitive behavior therapy (Moreina et al. 2015) as well as 
dynamic psychotherapy (Del Grande da Silva et al. 2016) lead to changes in TNF-α 
production. Thus, psychotherapy may influence the TNF-α system, independently of the 
specific diagnosis or the specific psychotherapeutic approach. Given that several other types 
of psychiatric treatment including psychopharmacological drugs (Himmerich et al. 2005, 
Kraus et al. 2002), relaxation training (Koh et al. 2008) and electroconvulsive therapy (Rotter 
et al. 2013) modulate the TNF-α system, an influence of psychotherapy on these parameters is 
also conceivable. However, in the current study, we cannot rule out that the changes in TNF-
α, sTNF-R p55 and sTNF-R p75 levels are a pure effect of time after deployment abroad. To 
investigate this thoroughly would require a control group suffering from combat-related 
PTSD receiving no treatment, which would have been ethically unjustifiable. Further 
longitudinal research into cytokine responses in relation to various stressors, emergence of 
disorders and during periods of treatment would likely be informative.  
Even though certain antidepressants are known to influence cytokine production (Kraus et al. 
2002), the use of antidepressants did not influence TNF-α, sTNF-R p55 and sTNF-R p75 
levels in our sample. As the patients in our sample used different types of antidepressants, we 
could only compare patients taking antidepressants with those using no antidepressant 
medication. As some antidepressants, such as venlafaxine (Kraus et al. 2002), may not 
influence TNF-α, sTNF-R p55 and sTNF-R p75 levels, our investigation is not suitable to 
study the influence of antidepressants on cytokine production specifically.  
A further limitation of this study is the small sample size of 38 patients in total, with 21 in the 
inpatient psychotherapy group. However, psychopharmacological agents, such as the 
antidepressant mirtazapine, the mood stabilizers lithium and carbamazepine and the 
antipsychotics olanzapine and clozapine, have been reported to influence the TNF-α system in 
studies with a comparable or smaller sample size (Kraus et al. 2002, Himmerich et al. 2005, 
Kluge et al. 2009).  
Another limitation of the present investigation is that sTNF-R p55 or sTNF-R p75 serum 
levels in these soldiers were not measured prior to deployment abroad. Such a longitudinal 
study design starting prior to deployment abroad would have enabled more specific 
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conclusions about a possible connection between PTSD and parameters of the TNF-α system. 
In addition, in the present study, we did not attempt to detect feigned PTSD or PTSD 
symptom exaggeration, in a standardized way, although measures for detecting malingering, 
such as specific scales of the Minnesota Multiphasic Personality Inventory-2 (MMPI-2), are 
available (Efendov et al. 2008). This issue might be specifically pertinent in soldiers because 
of eligibility for a state pension or other benefits if their PTSD is determined to be combat-
related and treatment-resistant. Therefore, one could question the initial PTSD diagnosis of 
these patients. However, the patients were assessed by an experienced military psychiatrist 
and obvious malingering would have obviated their inclusion in the study. 
In conclusion, to our knowledge, we performed the first study investigating the effect of 
psychiatric therapy and specifically inpatient psychotherapy including EMDR on serum levels 
of TNF-α, sTNF-R p55 or sTNF-R p75 in PTSD patients. The specific inpatient 
psychotherapy but also non-specific outpatient clinical management treatment reduced PTSD 
symptoms as measured by the PDS score and altered TNF-α, sTNF-R p55 and sTNF-R p75 
concentrations. It seems to be most likely that these changes are attributable to non-specific 
psychotherapeutic effect or side effects. From a methodological view, further confirmatory 
studies should incorporate a longitudinal design starting at the time before the deployment 
abroad, include a control group without any treatment, have a larger sample size and should 
try to detect feigned PTSD as well as PTSD symptom exaggeration. 
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Table 1: Mean and standard deviation (SD) of the descriptive variables age and body mass index (BMI) as well as the outcome parameters Post-
traumatic Stress Diagnostic Scale (PDS) score and serum concentrations of tumor necrosis factor-α (TNF-α) and its soluble receptors (sTNF-R) 
p55 and p75 separately for both treatment groups at baseline and after treatment. Regarding the whole group, there was a significant increase in 
TNF-α serum concentration (p<.01), but a significant decrease of sTNF-R p55 (p<.05) and sTNF-R p75 (p<.05) levels during the treatment 
period. Significant group differences in TNF-α parameters (inpatient vs. outpatient therapy) were not detected. 
 
  Inpatient psychotherapy 
(N=21) 




 Mean SD   Mean SD   
Age [years] 28.0 7.62   28.8 3.40   
BMI [kg/m2] 27.8 2.03   26.9 4.13   
Outcome 
Parameters 
 Baseline After treatment Baseline After treatment 
 Mean SD Mean SD Mean SD Mean SD 
PDS score 29.0 12.0 24.8 12.9 33.6 8.9 30.9 13.2 
TNF-α [pg/mL] 5.2 4.48 17.6 6.91 7.4 5.16 18.9 6.84 
sTNF-R p55 [pg/mL] 405.2 110.7 356.0 114.5 400.8 137.8 319.4 116.9 
sTNF-R p75 [pg/mL] 1412.0 439.8 1212 359.4 1250.0 375.2 1154 471.7 
 
 
